Comparative Effectiveness of Riamilovir and Umifenovir for Treating Influenza

The present study focuses on the comparative assessment of the therapeutic efficacy of the antiviral drugs riamilovir and umifenovir in the treatment of patients diagnosed with influenza. The aim of the study was to compare the clinical efficacy and safety, as well as the incidence of complications, of the use of antiviral drugs riamilovir and umifenovir and the use of only symptomatic therapy in patients with a confirmed diagnosis of influenza. All patients were hospitalized at the Regional Clinical Hospital No. 2 in Vladivostok. The study included 150 patients, who were divided into 3 groups (50 patients in each group), comparable in gender, age, and admission to the hospital. Patients of the first group received riamilovir, the second group received uminofenovir, patients of the third group received only symptomatic therapy (control group). The duration of clinical manifestations of the disease, hematological disorders, as well as the content of cytokines TNF-α and IL-10 in blood serum were assessed. The incidence of complications in each group was taken into account. As a result of the study, it was found that the inclusion of the antiviral drugs riamilovir and umifenovir in the therapy of influenza decreases the amount of the pro-inflammatory cytokine TNF-α after 5 days of treatment; and in case of symptomatic therapy its level significantly exceeded the reference values. The level of anti-inflammatory cytokine IL-10 on the 5^th day of treatment in the main group was three times lower than in the control group. Thus, riamilovir and umifenovir effectively relieve the main symptoms of the disease, reduce the incidence of complications, and reduce the severity of the inflammatory response by the 5^th day of treatment.

1. Maleev V.V. «Novye» respiratornye infektsii. Infektsionnye Bolezni. 2005; 3 (4): 5–7. (in Russian).

2. Maleev V.V., Sel'kova E.P., Prostyakov I.V., Osipova I.A. Farmakoepidemiologicheskoe issledovanie techeniya grippa i drugikh ORVI v sezone 2010/11 gg.. Infektsionnye Bolezni. 2012; 10 (3): 15–23. (in Russian).

3. Rukovodstvo po virusologii. D.K.L'vov (ed.). Virusy i virusnye infektsii cheloveka i zhivotnykh. Moscow: MIA; 2013.

4. Clinicheskie recomendacii Ministerstva Zdravoohranenia «Gripp u vzroslih», http://cr.rosminzdrav.ru/#!/recomend/909. (in Russian).

5. Sologub T.V., Tokin I.I., Midikari A.S., Tsvetkov V.V. A comparative efficacy and safety of using antiviral drugs in therapy of patients with influenza. Infektsionnye Bolezni. 2017; 15 (3): 40–47. doi: 10.20953/1729-9225-2017-3-25-32. (in Russian).

6. Kasianenko K.V., Lvov N.I., Maltsev O.V., Zhdanov K.V. Nucleoside analogues for the treatment of influenza: history and experience. Zhurnal Infektologii. 2019; 11 (3): 20–26. doi: 10.22625/2072-6732-2019-11-3-20-26. (in Russian).

7. Verevshchikov V.K., Shemyakina E.K., Sabitov A.U., Batskalevich N.A. Modern Etiotropic Therapy of Influenza and ARVI in Adult Patients with Premorbid Pathology. Antibiotiki i Khimioter. 2018; 63 (7–8): 47–50 (in Russian).

8. Tokin I.I., Zubkova T.G., Drozdova Yu.V., Lioznov D.A. Experience of etiotropic therapy of ARVI with a domestic antiviral drug. Infektsionnye Bolezni. 2019; 17 (4): 13–17. doi: 10.20953/1729-9225-2019-4-13-17. (in Russian).

9. Lioznov D.A., Tokin I.I., Zubkova T.G., Sorokin P.V. The practice of using a domestic antiviral drug in the etiotropic therapy of acute respiratory viral infection. Terapevticheskii Arkhiv. 2020; 92 (12): 160–164. doi: 10.26442/00403660.2020.12.200427. (in Russian).

10. Sabitov A.U., Belousov V.V., Edin A.S. et al. Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19. Antibiotiki i Khimioter. 2020; 65 (7–8): 27–30. doi: 10.37489/0235-2990-2020-65-7-8-27-30. (in Russian).

11. Kasyanenko K.V., Maltsev O.V., Kozlov K.V. et al. Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection. Antibiotiki i Khimioter. 2020; 65 (11–12): 16–21. doi: 10.37489/0235-2990-2020-65-11-12-16-21. (in Russian).

12. Sabitov A.U., Sorokin P.V., Dashutina S.Yu. The efficacy and safety of Riamilovir in the treatment of patients with COVID-19. Antibiotiki i Khimioter. 2021; 66: 1–2: 33–37. doi: 10.24411/0235-2990-2021-66-1–2-33-37. (in Russian).

13. Kasyanenko K.V., Kozlov K.V., Maltsev O.V., Lapikov I.I., Gordienko V.V., Sharabhanov V.V., Sorokin P.V., Zhdanov K.V. Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19. Terapevticheskii Arkhiv. 2021; 93 (3): 290–294. doi: 10.26442/00403660.2021.03.200719. (in Russian).

14. Bacci M., Leme R., Zing N., Murad N., Adami F., Hinnig P., Feder D., Chagas A.C.P., Fonseca F.L.A. IL 6 and TNF-a serum levels are as¬sociated with early death in community-acquired pneumonia patients. Braz J Med Biol Res. 2015; 48 (5): 427–432. doi: 10.1590/1414–431X20144402.

15. Endeman H., Rijkers G.T., Grutters J.C., Biesma D.H. Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J. 2011; 37 (6): 1431–1410. doi: 10.1183/09031936.00074410.

16. Suzuki T., Chow C-W., Downey G.P. Role of innate immune cells and their products in lung immunopathology. Int J Biochem Cell Biol. 2008; 40 (6–7): 1348–1361. doi: 10.1016/j.biocel.2008.01.003.

17. Wu E. K., Eliseeva S., Rahimi H., Schwarz E. M., Georas S. N. Restrictive lung disease in TNF-transgenic mice: correlation of pulmonary function testing and micro-CT imaging. Experimental Lung Research. 2019; 45: 175–187. doi: 10.1080/01902148.2019.1636899.

18. Shipilov M. V., Ivanov V. V. Interleikin-10 i ostrye respiratornye virusnye infektsii. Zdorov'e — Osnova Chelovecheskogo Potentsiala: Problemy i Puti Ikh Resheniya. 2011; 6 (1): 102–106. (in Russian).

19. Crisafulli E., Menendez R., Huerta A. et al. Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest 2013; 143: 1009–1017. doi: 10.1165/rcmb.2013–0386OC.

20. Virkki R., Juven T., Rikalainen H., Svedström E., Mertsola J., Ruuskanen O. Differentiation of bacterial and viral pneumonia in children. Thorax. 2002; 57 (5): 438–441. doi: 10.1136/thorax.57.5.438.

21. Simbirtsev A.S. Tsitokiny v patogeneze i lechenii zabolevanij cheloveka. Saint Petersburg: : Foliant, 2018; 512. (in Russian).